Literature DB >> 11698700

Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.

A M van Rossum1, H J Scherpbier, E G van Lochem, N G Pakker, W A Slieker, K C Wolthers, M T Roos, J H Kuijpers, H Hooijkaas, N G Hartwig, S P Geelen, T F Wolfs, J M Lange, F Miedema, R de Groot.   

Abstract

OBJECTIVE: To evaluate long-term immune reconstitution of children treated with highly active antiretroviral therapy (HAART).
METHODS: The long-term immunological response to HAART was studied in 71 HIV-1-infected children (aged 1 month to 18 years) in two prospective, open, uncontrolled national multicentre studies. Blood samples were taken before and after HAART was initiated, with a follow-up of 96 weeks, and peripheral CD4 and CD8 T cells plus naive and memory subsets were identified in whole blood samples. Relative cell counts were calculated in relation to the median of the age-specific reference.
RESULTS: The absolute CD4 cell count and percentage and the CD4 cell count as a percentage of normal increased significantly (P < 0.001) to medians of 939 x 106 cells/l (range, 10-3520), 32% (range, 1-50) and 84% (range, 1-161), respectively, after 48 weeks. This increase was predominantly owing to naive CD4 T cells. There was a correlation between the increase of absolute naive CD4 T cell counts and age. However, when CD4 T cell restoration was studied as percentage of normal values, the inverse correlation between the increase of naive CD4 T cell count and age was not observed. In addition, no difference in immunological reconstitution was observed at any time point between virological responders and non-responders.
CONCLUSIONS: Normalization of the CD4 cell counts in children treated with HAART is independent of age, indicating that children of all age groups can meet their CD4 T cell production demands. In general, it appears that children restore their CD4 T cell counts better and more rapidly than adults, even in a late stage of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698700     DOI: 10.1097/00002030-200111230-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

1.  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Authors:  Paul Krogstad; Kunjal Patel; Brad Karalius; Rohan Hazra; Mark J Abzug; James Oleske; George R Seage; Paige L Williams; William Borkowsky; Andrew Wiznia; Jorge Pinto; Russell B Van Dyke
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

2.  Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of Congo.

Authors:  Andrew Edmonds; Marcel Yotebieng; Jean Lusiama; Yori Matumona; Faustin Kitetele; David Nku; Sonia Napravnik; Stephen R Cole; Annelies Van Rie; Frieda Behets
Journal:  J Acquir Immune Defic Syndr       Date:  2012-09-01       Impact factor: 3.731

3.  Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials.

Authors:  Bret J Rudy; Bill G Kapogiannis; Michelle A Lally; Glenda E Gray; Linda-Gail Bekker; Paul Krogstad; Ian McGowan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

4.  Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART).

Authors:  Natascha Ching; Jaime G Deville; Karin A Nielsen; Bonnie Ank; Lian S Wei; Myung Shin Sim; Steven M Wolinsky; Yvonne J Bryson
Journal:  Eur J Pediatr       Date:  2006-07-26       Impact factor: 3.183

5.  Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.

Authors:  Mona Rigaud; William Borkowsky; Petronella Muresan; Adriana Weinberg; Phillip Larussa; Terry Fenton; Jennifer S Read; Patrick Jean-Philippe; Elaine Fergusson; Bonnie Zimmer; Dorothy Smith; Joyce Kraimer
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

6.  Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Authors:  Marie-Quitterie Picat; Joanna Lewis; Victor Musiime; Andrew Prendergast; Kusum Nathoo; Addy Kekitiinwa; Patricia Nahirya Ntege; Diana M Gibb; Rodolphe Thiebaut; A Sarah Walker; Nigel Klein; Robin Callard
Journal:  PLoS Med       Date:  2013-10-29       Impact factor: 11.069

7.  Quantification of CD4 Recovery in Early-Treated Infants Living With HIV.

Authors:  Juliane Schröter; Anet J N Anelone; Rob J de Boer
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-15       Impact factor: 3.771

8.  When should children with HIV infection be started on antiretroviral therapy?

Authors:  Steven B Welch; Di Gibb
Journal:  PLoS Med       Date:  2008-03-25       Impact factor: 11.069

9.  The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Authors:  Nigel Klein; Delali Sefe; Ilaria Mosconi; Marisa Zanchetta; Hannah Castro; Marianne Jacobsen; Hannah Jones; Stefania Bernardi; Deenan Pillay; Carlo Giaquinto; A Sarah Walker; Diana M Gibb; Anita De Rossi
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.